Allogene Craters To 52-Week Low On FDA Clinical Hold Of CAR-T Trials, Drags Peers As Well
The FDA has sent shockwaves through the off-the-shelf CAR-T space after it slapped a clinical hold
Goldman Sachs Downgrades Allogene Therapeutics to Neutral, Lowers Price Target to $20
Goldman Sachs analyst Salveen Richter downgrades Allogene Therapeutics (NASDAQ:ALLO) from Buy to Neutral and lowers the price target from $71 to $20.
UPDATE: Allogene Says ‘Testing in a Patient with Low Blood Counts Showed a Chromosomal Abnormality in ALLO-501A CAR T Cells of Unclear Clinical Significance; Patient Achieved a Partial Response to Therapy’
Testing in a Patient with Low Blood Counts Showed a Chromosomal Abnormality in ALLO-501A CAR T Cells of Unclear Clinical Significance; Patient Achieved a Partial Response to Therapy
Investigation Ongoing to Further
Raymond James Upgrades Allogene Therapeutics to Outperform, Announces $36 Price Target
Raymond James analyst Dane Leone upgrades Allogene Therapeutics (NASDAQ:ALLO) from Market Perform to Outperform and announces $36 price target.
Raymond James Upgrades Allogene Therapeutics to Outperform, Announces $36 Price Target
Raymond James analyst Dane Leone upgrades Allogene Therapeutics (NASDAQ:ALLO) from Market Perform to Outperform and announces $36 price target.
The Daily Biotech Pulse: Moderna’s Vaccine Produces Durable Response Against Variants, FDA Approves Jazz’s Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 12)
Allogene’s BCMA-Targeted Therapy Gets US Orphan Drug Tag For Multiple Myeloma
The FDA has granted Orphan Drug Designation to Allogene Therapeutics Inc’s (NASDAQ:ALLO) ALLO-715 to treat multiple myeloma. In April 2021, ALLO-715 received…
Stocks That Hit 52-Week Lows On Thursday
During Thursday's morning trading, 83 companies set new 52-week lows.